Cargando…
Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China
As of 29 February 2020 there were 79,394 confirmed cases and 2,838 deaths from COVID-19 in mainland China. Of these, 48,557 cases and 2,169 deaths occurred in the epicenter, Wuhan. A key public health priority during the emergence of a novel pathogen is estimating clinical severity, which requires p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094929/ https://www.ncbi.nlm.nih.gov/pubmed/32284616 http://dx.doi.org/10.1038/s41591-020-0822-7 |
_version_ | 1783510561031454720 |
---|---|
author | Wu, Joseph T. Leung, Kathy Bushman, Mary Kishore, Nishant Niehus, Rene de Salazar, Pablo M. Cowling, Benjamin J. Lipsitch, Marc Leung, Gabriel M. |
author_facet | Wu, Joseph T. Leung, Kathy Bushman, Mary Kishore, Nishant Niehus, Rene de Salazar, Pablo M. Cowling, Benjamin J. Lipsitch, Marc Leung, Gabriel M. |
author_sort | Wu, Joseph T. |
collection | PubMed |
description | As of 29 February 2020 there were 79,394 confirmed cases and 2,838 deaths from COVID-19 in mainland China. Of these, 48,557 cases and 2,169 deaths occurred in the epicenter, Wuhan. A key public health priority during the emergence of a novel pathogen is estimating clinical severity, which requires properly adjusting for the case ascertainment rate and the delay between symptoms onset and death. Using public and published information, we estimate that the overall symptomatic case fatality risk (the probability of dying after developing symptoms) of COVID-19 in Wuhan was 1.4% (0.9–2.1%), which is substantially lower than both the corresponding crude or naïve confirmed case fatality risk (2,169/48,557 = 4.5%) and the approximator(1) of deaths/deaths + recoveries (2,169/2,169 + 17,572 = 11%) as of 29 February 2020. Compared to those aged 30–59 years, those aged below 30 and above 59 years were 0.6 (0.3–1.1) and 5.1 (4.2–6.1) times more likely to die after developing symptoms. The risk of symptomatic infection increased with age (for example, at ~4% per year among adults aged 30–60 years). |
format | Online Article Text |
id | pubmed-7094929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-70949292020-03-26 Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China Wu, Joseph T. Leung, Kathy Bushman, Mary Kishore, Nishant Niehus, Rene de Salazar, Pablo M. Cowling, Benjamin J. Lipsitch, Marc Leung, Gabriel M. Nat Med Letter As of 29 February 2020 there were 79,394 confirmed cases and 2,838 deaths from COVID-19 in mainland China. Of these, 48,557 cases and 2,169 deaths occurred in the epicenter, Wuhan. A key public health priority during the emergence of a novel pathogen is estimating clinical severity, which requires properly adjusting for the case ascertainment rate and the delay between symptoms onset and death. Using public and published information, we estimate that the overall symptomatic case fatality risk (the probability of dying after developing symptoms) of COVID-19 in Wuhan was 1.4% (0.9–2.1%), which is substantially lower than both the corresponding crude or naïve confirmed case fatality risk (2,169/48,557 = 4.5%) and the approximator(1) of deaths/deaths + recoveries (2,169/2,169 + 17,572 = 11%) as of 29 February 2020. Compared to those aged 30–59 years, those aged below 30 and above 59 years were 0.6 (0.3–1.1) and 5.1 (4.2–6.1) times more likely to die after developing symptoms. The risk of symptomatic infection increased with age (for example, at ~4% per year among adults aged 30–60 years). Nature Publishing Group US 2020-03-19 2020 /pmc/articles/PMC7094929/ /pubmed/32284616 http://dx.doi.org/10.1038/s41591-020-0822-7 Text en © The Author(s), under exclusive licence to Springer Nature America, Inc. 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Letter Wu, Joseph T. Leung, Kathy Bushman, Mary Kishore, Nishant Niehus, Rene de Salazar, Pablo M. Cowling, Benjamin J. Lipsitch, Marc Leung, Gabriel M. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China |
title | Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China |
title_full | Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China |
title_fullStr | Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China |
title_full_unstemmed | Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China |
title_short | Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China |
title_sort | estimating clinical severity of covid-19 from the transmission dynamics in wuhan, china |
topic | Letter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094929/ https://www.ncbi.nlm.nih.gov/pubmed/32284616 http://dx.doi.org/10.1038/s41591-020-0822-7 |
work_keys_str_mv | AT wujosepht estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina AT leungkathy estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina AT bushmanmary estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina AT kishorenishant estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina AT niehusrene estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina AT desalazarpablom estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina AT cowlingbenjaminj estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina AT lipsitchmarc estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina AT leunggabrielm estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina |